Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2025 / Feb / Also in the News… (3)
Research & Innovations Anterior Segment Cornea Glaucoma Retina

Also in the News…

From AI-powered retinal screening technology to a new gene therapy for retinal dystrophy, these are the news stories and studies that caught our attention this week…

By Alun Evans 2/28/2025 1 min read

Share

Credit: Tarquin Binary - Own work, CC BY-SA 2.5, https://commons.wikimedia.org/w/index.php?curid=544527

510(K) clearance for New World Medical’s VIA360. US-based ophthalmic surgical device manufacturer, New World Medical, recently announced it has received 510(K) clearance from the FDA for its VIA360 Surgical System. The VIA360 is used for delivering controlled amounts of viscoelastic fluid during surgery and can also be used to cut trabecular meshwork tissue during trabeculectomy procedures. Link

AI-powered retinal screening for cardiovascular risk. The world’s first AI-powered cardiovascular retinal screening technology will be launched by Heart Eye Diagnostics at upcoming UK optical conferences, 100% Optical (March 1–3) and Optix 2025 (March 17–19). The company reports that the technology uses retinal imaging to test for patients’ risk of cardiovascular disease in only three minutes. Link

New retinal dystrophy gene therapy treatment. Young children with AIPL1-associated severe retinal dystrophy have gained life-changing improvements to their vision as a result of a new genetic treatment developed by the UCL Institute of Ophthalmology and Moorfields Eye Hospital, London, with support from MeiraGTx. The findings, published in The Lancet last week, show significant improvements in visual acuity, functional vision, and retinal preservation over 3–4 years in the four infants, indicating that early gene therapy intervention can provide substantial and lasting visual benefits for severe retinal dystrophies. Link

Glaucoma and the lungs. Lung function could act as a biomarker for glaucoma, says a new study from The Chinese University of Hong Kong. Using data from the UK Biobank to investigate the relationship between lung function and glaucoma, the authors found that lower lung function – measured by forced vital capacity (FVC), forced expiratory volume (FEV1), and FEV1/FVC ratio – is significantly associated with an increased risk of glaucoma. Mendelian randomization analyses suggest no causal relationship, indicating that impaired lung function may serve as a biomarker rather than a direct cause of glaucoma itself. Link

Genetic influences on retinal aging. Using transcriptomic and proteomic analyses across nine genetically diverse mouse strains, a new Molecular Neurodegeneration study has examined how genetic background influences retinal aging and degeneration. The study identified strain-specific aging signatures, with WSB mice showing severe photoreceptor loss resembling retinitis pigmentosa, and NZO mice exhibiting retinal ganglion cell degeneration and diabetic retinopathy-like vascular dysfunction. The findings highlight how genetic diversity can act as a key determinant in retinal aging and disease susceptibility. Link  
 

About the Author(s)

Alun Evans

More Articles by Alun Evans

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: